Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Winning with partnerships

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Nov 23, 2024 2:56pm

24 Views

Post# 36327534

RE:Winning with partnerships

Scarlet,
Can you tell if this is another Thera sponsored piece?

scarlet1967 wrote:
Winning With Partnerships: How To Turn A Three-Decade-Old Biotech Profitable

Winning With Partnerships: How To Turn A Three-Decade-Old Biotech Profitable

I don't have access to the article but as for partnerships I would love to know who, how many and when?

So far after few years "the position of strength/advanced talks..."for NASH have not resulted into anything at all.

The company was marginally profitable not due to a significant top line growth but firing some 40 percent of their employees only few years after hiring them.

One has to wonder if any of the board members were owner of this company privately would they be willing to approve the extravagant salaries and bonuses paid to certain executives despite their mismanagement of many aspects of the business side of the company. The author of this article has absolutely no knowledge of how this company has been mismanaged too many times. As others mentioned none of the overpaid upper management staff have lost significant amount of their NOT hard earned money compared to the longtime loyal investors! Articles like these are so misleading and sickening...